Related Experiment Video
Updated: Jun 10, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
[Effect analysis on non-and-low response infants after revaccinated hepatitis B vaccine]
Zhen-hua Wu1, Fu-qiang Cui, Xiao-hong Gong
1Union School of Public Health of Peking Union Medical College, Beijing 102200, China.
Insights
Booster immunizations significantly improve Hepatitis B (HepB) antibody titers in non- and low-response children. A three-dose booster regimen is more effective than a single dose for achieving high protective antibody levels.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Context:
- Hepatitis B (HepB) vaccination is crucial for preventing infection.
- Some children exhibit non- or low-response after initial HepB immunization.
- Booster doses are explored to enhance immunity in these individuals.
Purpose:
- To assess the effectiveness of booster immunizations in children with non- and low-response to primary HepB vaccination.
- To compare the serological outcomes of single-dose versus three-dose HepB booster regimens.
- To evaluate different formulations of HepB vaccines for booster efficacy.
Summary:
- A study involving non- and low-response infants demonstrated that a three-dose Hepatitis B (HepB) booster regimen significantly increased geometric mean concentrations (GMC) and the proportion of children with high antibody titers compared to a single dose.
- All tested HepB vaccine formulations (5 mcg HepB-Y, 10 mcg HepB-Y, 10 mcg HepB-CHO, 10 mcg HepB-HY) showed similar immunogenic effects after a three-dose booster schedule.
- While seroconversion rates were comparable between one and three doses, the three-dose booster resulted in significantly higher antibody titers.
Impact:
- Provides evidence supporting the use of a three-dose booster strategy to improve protective immunity against Hepatitis B in non- and low-responders.
- Suggests that multiple HepB vaccine formulations can be effectively used for booster immunizations.
- Contributes to optimizing vaccination schedules for vulnerable pediatric populations.
Objective:
To evaluate the booster immunization effect to non-and-low response children after 3 doses HepB immunization.
Methods:
Non-and-low response infants born in 2004 2005 administered 3 doses of HepB at 0, 1, 6 months in Guangzhou, Beijing and Zhejiang were divided into 4 groups randomly, and boosted 3 dose of 4 different types of HepB at 0, 1, 6 months.
Results:
The GMC of non-and-low response children in group A (before booster), group B (after 1 dose booster) and group C (after 3 dose booster) were 18.66 mIUml, 88.82 mIU/ml, 178.24 mIU/ml respectively; the proportion of non-responders in three groups were 20.4%, 9.1%, 1.9% respectively. In 103 non-and-low response children, proportion of titers of more than 100 mIU/ml of group B and group C were 61.2% and 84.5%, and there was statistical significant difference (chi2 = 14.13, P < 0.01). The GMC after 3 doses revaccination with four kinds of HepB, included 5 microg HepB-Y, 10 microg HepB-Y, l0 microg HepB-CHO, 10 microg HepB-HY were 168.8 mJU/ml, 174.7 mIU/ml, 184.9 mIU/ml, 182.9 mIU/ml respectively. Proportion of titers of more than 100 mIU/ml for four kinds HepB were 79.0%, 85.7%, 88.2% and 84.6% respectively, and there was no significant difference (chi2 = 0.75, 0.05).
Conclusion:
There were no different of seroconversion rate between study population received 1 dose and 3 dose booster (P > 0.05), but high titer was observed after 3 dose booster. The four kinds of HepB, including 5 microg HepB-Y,10 microg HepB-Y, 10 microg HepB-CHO, 10 microg HepB-HY had the same immunization effect after 3 doses revaccination at 0, 1, 6 months to non-and-low response children.
Related Concept Videos
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cross-reactivity
Factors Affecting Drug Response: Overview

